Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
ConclusionsIntegration of HLA ligandomics, transcriptomics, genetic, and epigenetic data leads to the identification of novel functionally relevant therapeutic targets for ccRCC immunotherapy. Validation of the identified targets is recommended to expand the treatment landscape of ccRCC.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Genetics | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma